Iovance Biotherapeutics Inc (IOVA) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Iovance Biotherapeutics Inc

NASDAQ | IOVA

3.25

USD

-0.295 (-8.33%)

AT CLOSE (AS OF Apr 3, 2025)

$1.2B

MARKET CAP

P/E Ratio

-1.28

EPS

$14

52 Week High

$3.2

52 Week Low

LIFE SCIENCES

Sector

IOVA Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

IOVA Technicals

Tags:

IOVA Earnings

Yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$9.6M
Total Revenue	$1.1M
Cost Of Revenue	$11M
Costof Goods And Services Sold	$11M
Operating Income	-$461M
Selling General And Administrative	$107M
Research And Development	$344M
Operating Expenses	$461M
Investment Income Net	$13M
Net Interest Income	$12M
Interest Income	$12M
Interest Expense	-
Non Interest Income	$1.1M
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$9.8M
Income Before Tax	-$448M
Income Tax Expense	-$3.5M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$444M
Comprehensive Income Net Of Tax	-$441M
Ebit	-$461M
Ebitda	-$451M
Net Income	-$444M

Revenue & Profitability

Earnings Performance

IOVA Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2023)

Field	Value (USD)
Total Assets	$780M
Total Current Assets	$308M
Cash And Cash Equivalents At Carrying Value	$115M
Cash And Short Term Investments	$280M
Inventory	$10M
Current Net Receivables	$151K
Total Non Current Assets	$406M
Property Plant Equipment	$114M
Accumulated Depreciation Amortization Ppe	$28M
Intangible Assets	$229M
Intangible Assets Excluding Goodwill	$229M
Goodwill	-
Investments	$199M
Long Term Investments	-
Short Term Investments	$165M
Other Current Assets	$17M
Other Non Current Assets	$270K
Total Liabilities	$196M
Total Current Liabilities	$110M
Current Accounts Payable	$33M
Deferred Revenue	-
Current Debt	-
Short Term Debt	$7.8M
Total Non Current Liabilities	$85M
Capital Lease Obligations	$75M
Long Term Debt	$1M
Current Long Term Debt	-
Long Term Debt Noncurrent	$1M
Short Long Term Debt Total	$1M
Other Current Liabilities	$69M
Other Non Current Liabilities	-
Total Shareholder Equity	$585M
Treasury Stock	-
Retained Earnings	-$2B
Common Stock	$11K
Common Stock Shares Outstanding	$256M

yearly Cash Flow (As of Dec 31, 2023)

Field	Value (USD)
Operating Cashflow	-$362M
Payments For Operating Activities	$17M
Proceeds From Operating Activities	-
Change In Operating Liabilities	$14M
Change In Operating Assets	$20M
Depreciation Depletion And Amortization	$12M
Capital Expenditures	$22M
Change In Receivables	$149K
Change In Inventory	$10M
Profit Loss	-$444M
Cashflow From Investment	-$155M
Cashflow From Financing	$463M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$463M
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$466M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	-$444M

yearly Income Statement (As of Dec 31, 2023)

Field	Value (USD)
Gross Profit	-$9.6M
Total Revenue	$1.1M
Cost Of Revenue	$11M
Costof Goods And Services Sold	$11M
Operating Income	-$461M
Selling General And Administrative	$107M
Research And Development	$344M
Operating Expenses	$461M
Investment Income Net	$13M
Net Interest Income	$12M
Interest Income	$12M
Interest Expense	-
Non Interest Income	$1.1M
Other Non Operating Income	-
Depreciation	-
Depreciation And Amortization	$9.8M
Income Before Tax	-$448M
Income Tax Expense	-$3.5M
Interest And Debt Expense	-
Net Income From Continuing Operations	-$444M
Comprehensive Income Net Of Tax	-$441M
Ebit	-$461M
Ebitda	-$451M
Net Income	-$444M

IOVA Profile

Iovance Biotherapeutics Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.

Most Active

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$103.14	-6.59%	$2.68T	263,349,217
LCID	$2.34	-2.30%	$7.67B	187,389,814
F	$9.68	-4.68%	$39.53B	173,285,336
PTIX	$0.43	91.50%	$4.04M	173,208,693

See more →

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
ABBV	$202.45	-1.34%	$364.89B	5,252,004
NVO	$67.60	-0.95%	$308.32B	7,033,051
AZN	$74.03	2.50%	$225.70B	6,150,517

See more →

Top Gainers

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.43	91.50%	$4.04M	173,208,693
MRM	$0.65	74.84%	$2.91M	51,693,935

See more →

Top Losers

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	20,249,631
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669